{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T20:38:50Z","timestamp":1786653530399,"version":"build-2736575974"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n                  <jats:sec>\n                    <jats:title>INTRODUCTION:<\/jats:title>\n                    <jats:p>Valproic acid (VPA) is a widely prescribed first-generation antiepileptic drug. It can induce different liver adverse effects (AEs) which range from mild to severe.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MATERIALS AND METHODS:<\/jats:title>\n                    <jats:p>\n                      A retrospective study was conducted by collecting 9-year reports (from January 2015 to June 2023) of VPA-associated hepatic AEs. It was collected in the Regional Center of Pharmacovigilance of Sfax (Tunisia). Causality was evaluated with the French B\u00e9gaud\n                      <jats:italic toggle=\"yes\">et al<\/jats:italic>\n                      . imputability method. Plasma VPA concentrations were measured using an automated enzyme immunoassay (INDIKO).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>We collected the eight cases of hepatic cytolysis with varying severity: Six had mild elevations of liver enzymes, one presented with moderately severe cytolysis and one case was fatal. There management strategies were guided by both transaminase levels and VPA concentrations. For those with alanine aminotransferase levels \u22655 times the upper limit of normal (ULN), we conducted the drug discontinuation. However, for patients with lower levels of transaminases, plasma VPA level measurement was recommended. The concentrations were within or near the ULN. Management consisted of either withdrawal or dose reduction, depending on associated clinical symptoms. Additional investigations to rule out nondrug-related causes performed in five cases were negatives. Most patients recovered favorable outcome after discontinuation or VPA dose reduction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>Management of VPA-induced hepatic cytolysis requires integrating the severity of liver enzyme elevations, plasma drug level measurements, and the results of etiological investigation to guide the clinical decisions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijp.ijp_1224_25","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T19:03:04Z","timestamp":1777575784000},"page":"266-271","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Hepatic adverse effects of valproic acid: Management strategies"],"prefix":"10.4103","volume":"58","author":[{"given":"Imen","family":"Bouaziz","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Regional Center of Pharmacovigilance, Pharmacology Laboratory, Faculty Bof Medicine of Sfax, Sfax, Tunisia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rim","family":"Atheymen","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Regional Center of Pharmacovigilance, Pharmacology Laboratory, Faculty Bof Medicine of Sfax, Sfax, Tunisia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rym","family":"Sahnoun","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Regional Center of Pharmacovigilance, Pharmacology Laboratory, Faculty Bof Medicine of Sfax, Sfax, Tunisia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamilia","family":"Ksouda","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Regional Center of Pharmacovigilance, Pharmacology Laboratory, Faculty Bof Medicine of Sfax, Sfax, Tunisia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanen","family":"Affes","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Regional Center of Pharmacovigilance, Pharmacology Laboratory, Faculty Bof Medicine of Sfax, Sfax, Tunisia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serria","family":"Hammami","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Regional Center of Pharmacovigilance, Pharmacology Laboratory, Faculty Bof Medicine of Sfax, Sfax, Tunisia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"Zghal","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Regional Center of Pharmacovigilance, Pharmacology Laboratory, Faculty Bof Medicine of Sfax, Sfax, Tunisia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,5,1]]},"reference":[{"key":"R1-20260501","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.clinbiochem.2013.06.012","article-title":"Adverse drug reactions induced by valproic acid","volume":"46","author":"Nanau","year":"2013","journal-title":"Clin Biochem"},{"key":"R2-20260501","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/20009666.2018.1514933","article-title":"Valproic acid induced acute liver injury resulting in hepatic encephalopathy- a case report and literature review","volume":"8","author":"Gayam","year":"2018","journal-title":"J Community Hosp Intern Med Perspect"},{"key":"R3-20260501","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/j.1528-1167.2007.01041.x","article-title":"Idiosyncratic adverse reactions to antiepileptic drugs","volume":"48","author":"Zaccara","year":"2007","journal-title":"Epilepsia"},{"key":"R4-20260501","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1056\/NEJMra021844","article-title":"Drug-induced hepatotoxicity","volume":"349","author":"Lee","year":"2003","journal-title":"N Engl J Med"},{"key":"R5-20260501","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3923\/crn.2011.1.14","article-title":"Epilepsy: Stigma and management","volume":"1","author":"Ahmad","year":"2011","journal-title":"Curr Res Neurosci"},{"key":"R6-20260501","doi-asserted-by":"crossref","first-page":"1","DOI":"10.54530\/jcmc.609","article-title":"Effect of different anticonvulsants on liver enzyme activities in patients with seizure disorder","volume":"12","author":"Dhungana","year":"2022","journal-title":"J Chitwan Med Coll"},{"key":"R7-20260501","first-page":"1","article-title":"Fulminant hepatitis induced by valproic acid: An exceptional iatrogenic accident in adults","volume":"9","author":"Bouomrani","year":"2019","journal-title":"J Gastrointest Dig Syst"},{"key":"R8-20260501","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1080\/15376516.2025.2459176","article-title":"Mechanisms involved in the valproic acid-induced hepatotoxicity: A comprehensive review","volume":"35","author":"Kadam","year":"2025","journal-title":"Toxicol Mech Methods"},{"key":"R9-20260501","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/FPC.0b013e32835ea0b2","article-title":"Valproic acid pathway: Pharmacokinetics and pharmacodynamics","volume":"23","author":"Ghodke-Puranik","year":"2013","journal-title":"Pharmacogenet Genomics"},{"key":"R10-20260501","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.3390\/jcm10061153","article-title":"Valproic acid-induced liver injury: A case-control study from a prospective pharmacovigilance program in a tertiary hospital","volume":"10","author":"Meseguer","year":"2021","journal-title":"J Clin Med"},{"key":"R11-20260501","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1093\/toxsci\/kfq294","article-title":"Role of oxidative metabolism in the effect of valproic acid on markers of cell viability, necrosis, and oxidative stress in sandwich-cultured rat hepatocytes","volume":"118","author":"Kiang","year":"2010","journal-title":"Toxicol Sci"},{"key":"R12-20260501","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1080\/03602530600959433","article-title":"Oxidative stress as a mechanism of valproic acid-associated hepatotoxicity","volume":"38","author":"Chang","year":"2006","journal-title":"Drug Metab Rev"},{"key":"R13-20260501","doi-asserted-by":"crossref","first-page":"117160","DOI":"10.1016\/j.taap.2024.117160","article-title":"Valproic acid-induced oxidative stress: Systematic review, meta-analysis and network pharmacology highlights disruption in antioxidant pathways in rodents","volume":"494","author":"Asghar","year":"2025","journal-title":"Toxicol Appl Pharmacol"},{"key":"R14-20260501","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.pediatrneurol.2017.09.013","article-title":"Antiepileptic drugs and liver disease","volume":"77","author":"Vidaurre","year":"2017","journal-title":"Pediatr Neurol"},{"key":"R15-20260501","first-page":"632","article-title":"Toxic liver:injury mechanisms and specific pharmacological therapies","volume":"16","author":"M\u00e9garbane","year":"2007","journal-title":"R\u00e9animation"},{"key":"R16-20260501","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13256-020-2343-x","article-title":"Valproate-induced hyperammonemic encephalopathy: A case report","volume":"14","author":"Shah","year":"2020","journal-title":"J Med Case Rep"},{"key":"R17-20260501","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1067\/S0190-9622(03)00748-5","article-title":"Fatal sodium valproate-induced hypersensitivity syndrome with lichenoid dermatitis and fulminant hepatitis","volume":"49","author":"Huang","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"R18-20260501","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1176\/appi.ajp.161.3.579","article-title":"Valproic acid and hypersensitivity syndrome","volume":"161","author":"Roepke","year":"2004","journal-title":"Am J Psychiatry"},{"key":"R19-20260501","first-page":"111","article-title":"Attribution of unexpected or toxic drug effects","volume":"40","author":"B\u00e9gaud","year":"1985","journal-title":"Update of the method used in France. Th\u00e9rapie"},{"key":"R20-20260501","doi-asserted-by":"crossref","first-page":"853","DOI":"10.3389\/fphar.2019.00853","article-title":"Roussel uclaf causality assessment method for drug-induced liver injury: Present and future","volume":"10","author":"Danan","year":"2019","journal-title":"Front Pharmacol"},{"key":"R21-20260501","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","article-title":"EASL clinical practice guidelines: Drug-induced liver injury","volume":"70","year":"2019","journal-title":"J Hepatol"},{"key":"R23-20260501","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/clpt.2011.58","article-title":"Case definition and phenotype standardization in drug-induced liver injury","volume":"89","author":"Aithal","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"R24-20260501","doi-asserted-by":"crossref","first-page":"48","DOI":"10.5698\/1535-7597-16.1.48","article-title":"Evidence-based guideline: Treatment of convulsive status epilepticus in children and adults: Report of the guideline committee of the American Epilepsy Society","volume":"16","author":"Glauser","year":"2016","journal-title":"Epilepsy Curr"},{"key":"R25-20260501","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/brain\/awh726","article-title":"Natural history of treated childhood-onset epilepsy: Prospective, long-term population-based study","volume":"129","author":"Sillanp\u00e4\u00e4","year":"2006","journal-title":"Brain"},{"key":"R26-20260501","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1600-0404.2008.01009.x","article-title":"Hepatotoxicity associated with antiepileptic drugs","volume":"118","author":"Bj\u00f6rnsson","year":"2008","journal-title":"Acta Neurol Scand"},{"key":"R27-20260501","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.seizure.2005.12.009","article-title":"Antiepileptic drugs and liver disease","volume":"15","author":"Ahmed","year":"2006","journal-title":"Seizure"},{"key":"R28-20260501","first-page":"15","article-title":"Drug-induced and non-drug-induced toxic liver diseases:general information","volume":"7","author":"Larrey","year":"2025","journal-title":"EMC Hepatology"},{"key":"R29-20260501","doi-asserted-by":"crossref","first-page":"59","DOI":"10.64719\/pb.4348","article-title":"Valproic acid and hepatic steatosis: A possible link?About a case report","volume":"46","author":"Mnif","year":"2016","journal-title":"Psychopharmacol Bull"},{"key":"R30-20260501","doi-asserted-by":"crossref","first-page":"S348","DOI":"10.14309\/00000434-201510001-00796","article-title":"A case of acute liver failure following initiation of valproic acid:796","volume":"110","author":"Morales","year":"2015","journal-title":"Off J Am Coll Gastroenterol"},{"key":"R31-20260501","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1177\/088307380001500215","article-title":"Fatality from hepatitis A in a child taking valproate","volume":"15","author":"Fayad","year":"2000","journal-title":"J Child Neurol"},{"key":"R32-20260501","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2515\/therapie\/2010029","article-title":"Therapeutic drug monitoring of valproate","volume":"65","author":"Bentu\u00e9-Ferrer","year":"2010","journal-title":"Therapie"},{"key":"R33-20260501","first-page":"685","article-title":"Evaluation of liver enzymes rising in patients treated with sodium valproate (VPA)","volume":"3","author":"Akhondian","year":"2015","journal-title":"Int J Pediatr"},{"key":"R34-20260501","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/hep.1840020513","article-title":"Valproate-induced hepatic injury: Analyses of 23 fatal cases","volume":"2","author":"Zimmerman","year":"2007","journal-title":"Hepatology (Baltimore, Md)"},{"key":"R35-20260501","doi-asserted-by":"crossref","first-page":"S197","DOI":"10.14309\/00000434-201210001-00473","article-title":"Valproic acid-induced acute liver failure:473","volume":"107","author":"Shahbaz","year":"2012","journal-title":"Off J Am Coll Gastroenterol"}],"container-title":["Indian Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijp.ijp_1224_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:38:59Z","timestamp":1786649939000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijp.ijp_1224_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/ijp.ijp_1224_25","relation":{},"ISSN":["0253-7613","1998-3751"],"issn-type":[{"value":"0253-7613","type":"print"},{"value":"1998-3751","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"2025-11-19","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-03","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}